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Abstract 1 
Objective: Acute mountain sickness (AMS) is defined by patient-reported symptoms 2 
using the Lake Louise Score (LLS), which does not necessarily provide insight into 3 
possible central nervous system (CNS) dysfunction. Our hypothesis was that AMS might 4 
be associated with cognitive impairment (CI) and may go undetected unless a sensitive 5 
test is applied. A standardized test for mild CI could provide a potential new tool to better 6 
characterize altitude-related CNS dysfunction.  7 
Methods: We compared a cognitive screening tool with the LLS. We recruited adult 8 
native English-speaking subjects visiting Himalayan Rescue Association aid posts in 9 
Nepal at 3520m (11,550ft) and 4550m (14,930ft). Subjects were administered the LLS 10 
and a slightly modified version of the Quick Mild Cognitive Impairment Screen (eQmci). 11 
Medication use for altitude illness was recorded. LLS and eQmci scores were compared 12 
using the Spearman correlation coefficient. A cut-off of  ≥3 with at least 1 point for 13 
headache was used for the LLS to diagnose AMS and 67 or less for the eQmci to 14 
diagnose CI. Data also included medication use.  15 
Results: Seventy-nine subjects were enrolled. Twenty-two (28%) subjects met criteria for 16 
AMS and 17 (22%) subjects met criteria for CI. There was a weak correlation (r2=0.06, 17 
p=0.04) between eQmci score and LLS. In matched subjects with identical LLS, recent 18 
acetazolamide use was significantly associated with more frequent CI.  19 
Conclusion: Field assessment of CI using a rapid standardized tool demonstrated a 20 
substantial number of subjects had mild CI following rapid ascent to 3520-4550m 21 
(11,548-14,927ft). The weak correlation between the LLS and eQmci suggests that AMS 22 
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is not associated with CI. Use of acetazolamide may have an association with CI at all 1 
levels of AMS severity.  2 
  3 
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Introduction 1 
 2 
Acute mountain sickness (AMS) commonly occurs following acute exposure to high 3 
altitude (> 2,500m or 8200 ft) (Hackett & Roach, 2012; Wilson & Imray, 2009). AMS is 4 
defined by symptoms including headache, dizziness or lightheadedness, nausea and 5 
vomiting, difficulty sleeping, and fatigue. The Lake Louise self-reported score (LLS) is 6 
one of the most widely used diagnostic scoring systems to diagnose AMS (Roach et al., 7 
1993). 8 
 9 
Previous work has suggested the possibility of cognitive impairment (CI) in AMS. While 10 
it is known high altitude conditions can impair cognition, and alter executive, memory 11 
and language processes (Asmaro et al., 2013; Du et al., 1999; Kramer et al., 1993; Li et 12 
al., 2000; McCarthy et al., 1995; Petrassi et al., 2012; Turner et al., 2015; Virues-Ortega 13 
et al., 2004; Wu et al., 1998), it is generally accepted that altitude-related CI occurs 14 
independently of AMS (Kramer et al., 1993; Virues-Ortega et al., 2004). However, some 15 
studies do suggest CI and AMS are associated (Bian et al., 2015; Forster, 1985; Regard et 16 
al., 1991, Shukitt-Hale et al., 1991, Issa et al., 2016). AMS is a symptom complex that 17 
may be due to early, mild cerebral edema and increased intracranial pressure (Lawley et 18 
al., 2016; Sagoo et al., 2016). Cerebral manifestations of acute altitude illness span from 19 
common, benign AMS to potentially fatal high altitude cerebral edema (HACE).  AMS 20 
has no obvious neurologic signs (e.g., ataxia), but these are found in HACE. Because 21 
high altitude cerebral illnesses appear to be a continuum from the mild symptoms of 22 
AMS to severe symptoms with overt CNS findings of HACE, our hypothesis was that a 23 
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sensitive objective test for high altitude-related mild CI using an easily available field 1 
technique would correlate closely with the presence and severity of AMS. 2 
 3 
The Quick Mild Cognitive Impairment (Qmci) screen has potential to detect mild CI in 4 
the field at high altitude. The Qmci screen rapidly and reliably detects early mild CI 5 
(Molloy et al., 2005; O'Caoimh et al., 2012). We tested a slightly modified version of the 6 
Qmci (which we refer to as the Environmental Quick Mild Cognitive Impairment Screen 7 
(eQmci)) and sought to determine if AMS is associated with CI. We compared the eQmci 8 
to the LLS and screened for medication by use of drugs for prophylaxis of AMS.  9 
 10 
Methods 11 
Study Population 12 
All of our subjects had recently and rapidly ascended by vehicle and foot to the two 13 
testing sites in the Annapurna region of the Nepalese Himalayas. Adult native English 14 
speaking subjects visiting the Himalayan Rescue Association aid post in Manang at 3520 15 
m (11,550 ft) or at a temporary aid post in Thorong Phedi at 4550 m (14,930 ft) were 16 
offered enrollment into the study. Surveys were only offered to clinically stable subjects 17 
at the end of their medical visit after clearance from the health professional caring for 18 
them. Inclusion criteria included native English-speaking adults between the ages of 18 19 
and 65 years trekking through Manang or Thorong Phedi. This included asymptomatic 20 
subjects who presented themselves to the clinic for education and prevention of illness. 21 
Subjects were not excluded for having minor ailments including joint pain, blisters, 22 
rashes, diarrhea and cough. Exclusion criteria included a history of dementia and 23 
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recreational drug or alcohol use. All recruited subjects were trekkers who had ascended 1 
from 8000 ft (2440 m) within 1 week. No permanent residents of high altitude were 2 
recruited.  3 
 4 
Study Procedures 5 
Subjects who presented to the aid posts meeting criteria were enrolled. A consent 6 
document with information about the study was presented to each volunteer and written 7 
consent was obtained. Information collected from each subject included age, years of 8 
education, history of dementia, fluency in English, rate of ascent, medication use, and 9 
self-rated high altitude experience. Subjects were asked about prophylactic and treatment 10 
medications for high altitude illness, analgesics and any potentially sedating drugs during 11 
their trek through the Annapurna region. Medications for general medical problems (e.g. 12 
antihypertensives, oral contraceptives, thyroid replacement, etc.) were not recorded. Each 13 
subject enrolled was administered the LLS and eQmci by a single investigator. This study 14 
was approved (Protocol number 2014P001803) by the Partners Institutional Review 15 
Board (Boston, MA, USA) and Nepali Health Research Council.   16 
 17 
Testing 18 
The LLS uses a 5-item scale, which surveys a subject’s assessment of headache, 19 
dizziness or lightheadedness, fatigue or weakness, gastrointestinal distress, and difficulty 20 
sleeping. Each symptom is graded on a scale of 0 (not present) to 3 (severe). The 21 
presence of a headache (score at least one for headache) and a total score of greater than 22 
or equal to 3 is required to diagnose AMS (Roach et al., 1993).  23 
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 1 
The Qmci consists of 6 subtests including orientation, registration, clock drawing, 2 
delayed recall, verbal fluency and logical memory. It has a median administration time of 3 
4.24 minutes (O'Caoimh et al., 2013). The range of score is 0 to 100. Two modifications 4 
were made to better apply this screen in high altitude wilderness settings. We removed 5 
the clock drawing task given the practical concern of needing to remove gloves to 6 
perform the test in a very cold environment. The clock drawing test is useful to assess 7 
visuospatial cognition, but is clinically a less useful subtest when compared to other 8 
elements in the Qmci (O'Caoimh et al., 2013). Instead, in order to maintain a distracting 9 
task before the verbal recall exam, subjects were asked to count backwards from 100 by 10 
sevens. A second modification was made in which proper names replaced common 11 
names for repetition and recall testing. Proper names were matched for frequency of 12 
occurrence in the English language. High altitude seems to have a more dramatic effect 13 
on the recall of proper names while recall of common names is relatively resistant to 14 
hypoxia (Pelamatti et al., 2003). The remaining subtests were unchanged. Subjects with 15 
normal cognition have a median score of 75 (O’Caoimh R, 2014). Subjects who score ≤ 16 
67 out of 100 meet criteria for mild CI and those who score ≤ 53 out of 100 meet criteria 17 
for dementia (O’Caoimh R, 2014).  18 
 19 
Statistical Analysis 20 
Continuous variables were compared using two-sample t-tests while categorical variables 21 
were measured using frequency and percentage and compared using chi-square tests. The 22 
relationship between the two measures was summarized using a Spearman correlation 23 
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coefficient. Two-sided p values ≤ 0.05 were considered as statistically significant. All 1 
analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). 2 
 3 
Results 4 
Seventy-nine subjects were enrolled in the study. All subjects who enrolled completed 5 
the surveys. Twenty-two subjects (28 %) met criteria for AMS and 17 subjects (22 %) 6 
met criteria for mild CI.  7 
 8 
Table I presents demographic subject information stratified by presence of AMS and CI. 9 
We found a significant difference in recent acetazolamide use between groups with and 10 
without AMS. Twenty-three out of 79 (29 %) took acetazolamide in the last 24 hours. Of 11 
these subjects, 10 (43 %) had AMS and 11 (48 %) had CI. A higher percentage of 12 
subjects diagnosed with AMS had taken acetazolamide in the previous 24 hours 13 
compared to those without AMS (45 % vs. 23 %, p = 0.047). Similarly, a higher 14 
percentage of subjects with CI had taken acetazolamide in the last 24 hours compared to 15 
those without CI (65 % vs. 19 %, p = 0.0003).  Subjects with CI were slightly older (37 ± 16 
14 vs. 29 ± 9, p = 0.058) and there were no other significant differences in group 17 
characteristics [e.g. age, sex, nationality, education, days above 8000 ft, self-rated 18 
experience at high altitude, and paracetamol and non-steroidal anti-inflammatory 19 
(NSAID) use] in subjects with and without AMS, or with and without CI. 20 
 21 
As this study tested subjects at two different altitudes, we also analyzed the results from 22 
only Manang, where the majority of subjects were recruited (n = 62). When subjects from 23 
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Thorong Phedi were excluded, there was still a significant difference in recent 1 
acetazolamide use between groups with and without AMS. Specifically, a higher 2 
percentage of subjects diagnosed with AMS had taken acetazolamide in the last 24 hours 3 
compared to those without AMS (44 % vs. 13 %, p = 0.009). Similarly, a higher 4 
percentage of subjects with CI had taken acetazolamide in the last 24 hours compared to 5 
those without CI (54 % vs. 12 %, p = 0.001).  There were no other significant differences 6 
in group characteristics. 7 
 8 
There was a very weak correlation between the eQmci score and LLS based on the 9 
Spearman correlation coefficient (r = - 0.24, p = 0.04) as only 5% of the variance in the 10 
eQmci can be attributed to LLS (see Figure 1). Among the 79 subjects, 6 (8 %) tested 11 
positive for both AMS and CI and 46 (58 %) tested negative for both. Sixteen subjects 12 
(20 %) met the LLS criteria for AMS but had no CI. The remaining 11 subjects (14 %) 13 
were cognitively impaired but did not have AMS.  Those with concordance between the 14 
eQmci and LLS were more likely to be male (69 % vs. 41 %, p = 0.014) and there was no 15 
other significant difference in subject demographic characteristics between those with 16 
and without concordance between the eQmci and LLS. 17 
 18 
Components of the LLS were also analyzed as presented in Table II. There was no strong 19 
correlation between the eQmci score and any of the LLS components, including 20 
headache. The strongest correlation was seen in gastrointestinal symptoms, which was 21 
still relatively weak (r = -0.28, p = 0.011).  22 
 23 
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We conducted a further analysis to examine the effect of acetazolamide on eQmci score. 1 
Figure 2 shows the distribution of eQmci from those subjects with and without 2 
acetazolamide use in the last 24 hours. The overall mean eQmci scores were lower in 3 
subjects who took acetazolamide (69 vs. 77, p = 0.0007). The finding was consistent 4 
when limited to subjects with the same LLS score.  Table III compares the prevalence of 5 
CI from subjects with and without acetazolamide use in the last 24 hours. Overall, CI 6 
were more common among subjects with acetazolamide use (47.8% vs. 10.7 %, p = 7 
0.0006). When stratified by AMS status, the finding remained consistent.  Among those 8 
without AMS, CI was significantly more frequent in subjects who took acetazolamide 9 
than in subjects who had not taken the drug (46.2 % vs. 11.4 %, p = 0.011). Similarly, 10 
among subjects with AMS, those who took acetazolamide showed a trend to have more 11 
CI (50.0 % vs. 8.3 %, p = 0.056) than those who had not taken the drug.   12 
 13 
Discussion 14 
Acute ascent to high altitude can impair CNS function including short-term memory, 15 
working memory, and executive functioning (Asmaro et al., 2013; de Aquino Lemos et 16 
al., 2012; Hornbein et al., 1989; Kennedy et al., 1989; Kramer et al., 1993; Petiet et al., 17 
1988; Petrassi et al., 2012; Shukitt-Hale et al., 1994; Turner et al., 2015; Virues-Ortega et 18 
al., 2004). We hypothesized that a field test for mild CI would provide an objective 19 
measure of altitude-related CNS dysfunction which would correlate with the presence 20 
and severity of AMS. Our results do not suggest a significant correlation between the 21 
eQmci and LLS to support this hypothesis. 22 
 23 
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Lack of relationship between cognitive impairment and acute mountain sickness 1 
The lack of correlation between the LLS and eQmci suggests that CI occurs 2 
independently of AMS.  This is consistent with previous research (Virues-Ortega et al., 3 
2004). Krammer et al. (1993) tested twenty climbers at 4360 m (14,304 ft) ascending 4 
Denali. While they demonstrated deficits in learning and retention in perceptual and 5 
memory tasks, they did not correlate with AMS. In one study that tested mental capacity, 6 
subjects with AMS were worse in pursuit aiming compared to subjects without AMS, but 7 
in the remaining battery of cognitive tests, no significant differences were found (Bian et 8 
al., 2015). It is possible that there is a difference in the aspects of cognitive deficits seen 9 
with and without AMS. In the study by Regard et al. (1991), subjects simulated ascent to 10 
4500 m (14,734 ft) over 24 hours in a hypobaric chamber. Those with AMS had 11 
deficiencies in short-term memory, but improved in conceptual tasks while those without 12 
AMS had improved short-term memory, but no improvement in conceptual tasks (Regard 13 
et al., 1991). 14 
 15 
The lack of any relationship in our study and in others between CI and AMS, both of 16 
which are inextricably linked to the hypoxemia of high altitude and are largely 17 
neurological in their expression, is somewhat counterintuitive.   However, hypoxemia can 18 
very rapidly lead to cognitive deficits (usually without symptoms) in a span of minutes 19 
even in healthy persons, whereas AMS develops more slowly and generally is not evident 20 
for many hours.  Furthermore, people differ widely in the risk for AMS as a result of 21 
varying sensitivity to hypoxemia involving pathways not fully understood, but possibly 22 
related to trigeminal nerve sensitivity and/or very mild brain swelling that may not 23 
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necessarily impair neuronal functioning.  Thus CI at high altitude and AMS likely have 1 
different pathophysiological bases, but may coexist in some people on any occasion.  2 
 3 
Cognitive impairment at altitude 4 
 Our study found a surprisingly high prevalence of CI: 17 subjects (22 %) met criteria for 5 
mild CI. In subjects with an age range similar to that in our study, no subject tested at 6 
sea-level was found to have CI (Molloy, 2015). An incidental finding of our study was 7 
that acetazolamide use, independent of the severity of AMS was associated with CI at 8 
high altitude.  9 
 10 
The discriminating power of the Qmci for detecting CI is influenced by age; specifically 11 
it is less accurate for subjects older than 75 years (O’Caoimh, 2014). The cut-off of 67 12 
used in this study is recommended for younger adults (≤ 75 years) with more education 13 
(≥ high school). All subjects in our study were in this category. At this cut-off the Qmci 14 
has 86 % sensitivity and 89 % specificity for detecting the presence of mild CI. CI is not 15 
seen in a young healthy educated population (Molloy, 2015). Sex does not significantly 16 
affect cut-off scores (O’Caoimh R, 2014). 17 
 18 
Acetazolamide and cognitive impairment 19 
In subjects taking acetazolamide, we found a high incidence of both AMS and of CI. 20 
Acetazolamide has been associated with confusion (Swenson, 2014). In a randomized 21 
study of subjects at high altitude, subjects who received prophylactic acetazolamide (125 22 
mg twice per day) had impaired neuropsychological measures of concentration, cognitive 23 
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processing speed, reaction time, short-term memory, and working memory (Wang et al., 1 
2013). In a similar study, subjects who took acetazolamide (500 mg slow release, once 2 
per day) actually showed improvement in certain psychological tests (White, 1984). In 3 
addition to higher daily acetazolamide dosing, this second study differed from the former 4 
in that subjects traveled on foot rather than being airlifted to a higher altitude which may 5 
be a confounding factor. A more recent study found that at sea level, acetazolamide use is 6 
associated in a dose-dependent fashion with a spectrum of psychometric impairments, 7 
including poor concentration, imbalance and slower reaction time responses (Collier, 8 
2016). Our study did not differentiate between prophylactic or treatment doses, but a 9 
future study can be designed to match groups with regard to this variable. Physiologically, 10 
acetazolamide functions as a carbonic anhydrase (CA) inhibitor. CA plays a role in signal 11 
processing, synaptic plasticity, memory, nerve conduction and cerebral oxygenation and 12 
consumption (Brechue et al., 1997; Sun & Alkon, 2002; Wang et al., 2015). CA 13 
inhibition is likely responsible for the deficits in cognition. Whether CI arises from the 14 
drug-induced metabolic acidosis that partially compensates for the magnitude of the 15 
respiratory alkalosis (hypocapnia) or from more direct effects in the CNS is not easily 16 
resolved, but a combination of the two may be likely. At sea level only 50 % of patients 17 
taking acetazolamide (250 mg, four times a day) have relief of common CNS side effects 18 
with concurrent bicarbonate supplementation sufficient to correct the metabolic acidosis 19 
(Lichter, 1981). 20 
 21 
Limitations of the study 22 
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There are several limitations in this investigation. First, we made modifications to the 1 
eQmci (the clock drawing task was replaced by reciting serial sevens and the repetition 2 
and recall of names were changed from common to proper). Though the Qmci has been 3 
validated against the Montreal Cognitive Assessment and Standardized Mini-Mental 4 
State Exam, the two minor changes in the eQmci were not validated prior to testing. This 5 
potentially could have an effect on the cut-off values originally tested for the Qmci. 6 
Second, traveling to a distant, culturally unfamiliar location may alter one’s performance 7 
on a cognitive test. Third, there was a relatively small sample size. Other trends may be 8 
been seen with a more robust sample. Unfortunately, our recruitment was limited as a 9 
result of the devastating 2015 earthquake in Nepal, which resulted in premature 10 
termination. Fourth, there may be several secondary influences on neuropsychological 11 
function including fatigue, hypothermia, desynchronosis, upper respiratory infections, 12 
and exposure to a new environment. An individual diagnosis was not recorded for every 13 
patient. However, most presentations to the clinic that were unrelated to altitude were 14 
quite minor (e.g. blisters) and would not be expected to affect cognitive function. Fifth, 15 
there was no low-altitude control group, nor were our subjects tested at low altitude to 16 
examine baseline scores. Sixth, there were no measurements of arterial oxygenation 17 
saturation by pulse oximetry. In future studies, this would be a better indicator of cerebral 18 
hypoxic stress than the actual altitude. Seventh, there were no longitudinal data to 19 
determine if low eQmci scores correlate with the development of HACE. Defining the 20 
clinical significance of mild CI and determining whether it can it be used to predict those 21 
that will develop HACE or experience other clinical relevant sequelae are areas of future 22 
research. In addition, there were no longitudinal data on the discontinuation of 23 
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acetazolamide. Eighth, subjects were studied at two different altitudes. However, the 1 
results were not significantly changed when the data were limited to Manang, where most 2 
subjects were tested. Ninth, in a convenience sample, in which subject self-selection 3 
exists (researchers have no control or insight in subjects’ decisions to continue to ascend 4 
or not), unmeasured confounding variables may exist that could reduce the validity of our 5 
conclusions.   6 
 7 
Future Studies 8 
Regardless of AMS, screening of mild CI may be useful for early detection of impaired 9 
cognition and poor decisional judgment at high altitude. Our study, however, does not 10 
demonstrate any clinical significance of having mild CI diagnosed by a cognitive 11 
function test, since we did not measure rates of adverse health events or poor decision-12 
making, but this is a potential area of future research. Cognitive tests are sensitive and 13 
have the potential to screen for hypoxic impairment at early stages before subjects 14 
develop symptoms or demonstrate poor judgment (Stepanek et al., 2013). Other cognitive 15 
tests have been employed at high altitude such as clock drawing (Quigley & Zafren, 16 
2016). The eQmci can be administered in less than five minutes, does not require any 17 
special equipment, and has multiple versions available to minimize a learning effect 18 
when administered to the same subject over different points in time (Cunje et al., 2007). 19 
Future longitudinal studies in trekkers, as well as validation of the eQmci and comparison 20 
to other cognitive tests, may be useful to investigate the clinical relevance of mild CI. 21 
Further study of secondary influences on CI at high altitude (e.g. exercise, medications, 22 
sleep quality) are also needed. Lastly, the comparison of CI with other objective 23 
Acute Mountain Sickness and Cognition  
 
 16 
measures (e.g., optic nerve sheath diameter, ultrasonography, cerebral magnetic 1 
resonance imaging, serum biomarkers) might help advance a better understanding of 2 
acute altitude-related CNS disease.  3 
 4 
In summary, our data demonstrate only a weak correlation between the LLS and eQmci, 5 
but a surprising prevalence of CI, an objective measure of CNS dysfunction, at high 6 
altitude. CI was prevalent in subjects both with and without AMS. The presence of CI in 7 
otherwise asymptomatic trekkers raises concerns for unrecognized CI at altitude. 8 
Furthermore, we found that acetazolamide use, independent of the severity of AMS was 9 
associated with CI at high altitude. Further research using CI testing may help define 10 
objective measures of CNS dysfunction at altitude.  11 
 12 
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 18 
 19 
Table and Figure Legend 20 
Table I: Basic demographics. Percentages are reported with respect to different subgroups 21 
(LLS <3, LLS ≥ 3, eQmci > 67, eQmci ≤ 67). 22 
 23 
Acute Mountain Sickness and Cognition  
 
 17 
Table II: Analysis of components of the LLS Associated with the eQmci score is 1 
demonstrated with relatively weak correlation. 2 
 3 
Table III: The relationship between eQmci scores and acetazolamide use were analyzed. 4 
The overall mean eQmci scores were significantly lower in subjects that took 5 
acetazolamide. 6 
 7 
Figure 1: A scatter plot was created between LLS and eQmci scores. There was poor 8 
correlation between the eQmci score and the LLS based on the Spearman (-0.24) 9 
correlation coefficients. 10 
 11 
Figure 2: A graphic display of the range of values for the eQmci in subjects with and 12 
without acetazolamide use in the last 24 hours. eQmci scores were lower in subjects who 13 
took acetazolamide (p<0.001). 14 
 15 
 16 
 17 
 18 
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